P. Joy Ho

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster, Michael Bishop, Constantine S. Tam et al. · New England Journal of Medicine · 2018 · 4K citations · Full text

Medicine, Hematology, Oncology +15

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Jesús F. San Miguel, Binod Dhakal, Kwee Yong et al. · New England Journal of Medicine · 2023 · 733 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia

Alexis A. Thompson, Mark C. Walters, Janet L. Kwiatkowski et al. · New England Journal of Medicine · 2018 · 661 citations · Full text

Medicine, Genetics, Hematology +16

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster, Constantine S. Tam, Peter Borchmann et al. · The Lancet Oncology · 2021 · 561 citations

Medicine, Hematology, Oncology +9

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Fowler, Michael Dickinson, Martin Dreyling et al. · Nature Medicine · 2021 · 527 citations · Full text

Medicine, Hematology, Oncology +12